KR20190072521A - 치매를 치료하기 위한 조성물 - Google Patents

치매를 치료하기 위한 조성물 Download PDF

Info

Publication number
KR20190072521A
KR20190072521A KR1020197010138A KR20197010138A KR20190072521A KR 20190072521 A KR20190072521 A KR 20190072521A KR 1020197010138 A KR1020197010138 A KR 1020197010138A KR 20197010138 A KR20197010138 A KR 20197010138A KR 20190072521 A KR20190072521 A KR 20190072521A
Authority
KR
South Korea
Prior art keywords
estradiol
acid
combination
dementia
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197010138A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 호프만
Original Assignee
스티븐 호프만
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 호프만 filed Critical 스티븐 호프만
Publication of KR20190072521A publication Critical patent/KR20190072521A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197010138A 2016-09-12 2017-09-08 치매를 치료하기 위한 조성물 Withdrawn KR20190072521A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662393140P 2016-09-12 2016-09-12
US62/393,140 2016-09-12
US201762507531P 2017-05-17 2017-05-17
US62/507,531 2017-05-17
PCT/US2017/050653 WO2018049141A1 (en) 2016-09-12 2017-09-08 Compositions for treating dementia

Publications (1)

Publication Number Publication Date
KR20190072521A true KR20190072521A (ko) 2019-06-25

Family

ID=59901615

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010138A Withdrawn KR20190072521A (ko) 2016-09-12 2017-09-08 치매를 치료하기 위한 조성물

Country Status (12)

Country Link
US (1) US10300077B2 (https=)
EP (1) EP3509639A1 (https=)
JP (1) JP2019526612A (https=)
KR (1) KR20190072521A (https=)
CN (2) CN110177572A (https=)
AU (1) AU2017322332A1 (https=)
BR (1) BR112019004540A2 (https=)
CA (1) CA3036511A1 (https=)
IL (1) IL265255A (https=)
MX (1) MX2019002673A (https=)
PH (1) PH12019500479A1 (https=)
WO (1) WO2018049141A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161442A (ja) * 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
JP4609875B2 (ja) * 2001-07-31 2011-01-12 有限会社大長企画 健康食品
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
CA2602386A1 (en) * 2005-03-25 2006-10-05 Merck & Co., Inc. Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
CA2623839C (en) * 2005-09-26 2013-12-17 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
WO2008016768A1 (en) * 2006-08-02 2008-02-07 Roberta Diaz Brinton Phytoestrogenic formulations and uses thereof
BRPI1015472A2 (pt) * 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
WO2014194166A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease

Also Published As

Publication number Publication date
CN114796236A (zh) 2022-07-29
CA3036511A1 (en) 2018-03-15
IL265255A (en) 2019-05-30
WO2018049141A1 (en) 2018-03-15
JP2019526612A (ja) 2019-09-19
EP3509639A1 (en) 2019-07-17
US20180071316A1 (en) 2018-03-15
WO2018049141A4 (en) 2018-05-03
MX2019002673A (es) 2019-07-04
PH12019500479A1 (en) 2019-07-29
AU2017322332A1 (en) 2019-04-04
CN110177572A (zh) 2019-08-27
BR112019004540A2 (pt) 2019-05-28
US10300077B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
JP7806187B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
US12415829B2 (en) Progesterone phosphate analogs and uses related thereto
KR20190072521A (ko) 치매를 치료하기 위한 조성물
US11274118B2 (en) Progesterone analogs and uses related thereto
JP2016527307A5 (https=)
AU2006229840B2 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
IL153540A (en) Use of steroids with group 7ß - hydroxy for the preparation of pharmaceutical preparations
JP2019526612A5 (https=)
ES2423493T3 (es) Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC
JP6368219B2 (ja) エストロゲン受容体β活性化剤
TW201311659A (zh) 新穎醫藥組成物
Zhu et al. Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
DECKER Pregnenolone & Its Metabolites: Central Nervous System Effects.
JPH08512305A (ja) 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用
EP4460506A1 (en) Estradiol prodrugs and methods of use thereof
EP4619106A2 (en) Treatment of asct2-dependent cancers
TW200730180A (en) Therapeutic uses of steroidal compounds
RU2007141204A (ru) Способы лечения заболеваний, связанных с состоянием тревоги
Smith Effects of Estrogens on Astrocytes Exposed to Stressors
CN110430883A (zh) 用于医学治疗的3β-羟基-5α-孕烷-20-酮

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190409

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200908

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210329

WITB Written withdrawal of application